Stage
No active trials
Next date
None yet
Trials
0 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Alopecia Areata, Alopecia, Alopecia Totalis, Alopecia Universalis
- Main trialPhase 2
- “The purpose of this study is to assess the safety, PK, and PD of EQ101 as well as measure the efficacy of EQ101 at Week 24 compared to Baseline in adult subjects with moderate to severe AA. The study consists of 3 phases: a screening phase of up to 5 weeks, a treatment phase of 24 weeks, and a follow-up phase of 4 weeks. Study drug will be administered via intravenous (IV) push weekly.”In the company’s words, NCT05589610 on ClinicalTrials.gov
Other drugs for Alopecia Areata
- RitlecitinibPfizer · Phase 3
- DeuruxolitinibSun Pharma · Phase 3
- UpadacitinibAbbVie · Phase 3
- ALD-102Aldena Therapeutics · Phase 1/2
- SYHX1901CSPC · Phase 2
- LAD603Almirall, S.A. · Phase 2
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Completed | 26 Mar 2024 | Study of EQ101 in Adult Subjects With Moderate to Severe Alopecia Areata |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026